Decision by Bayer's Management Board: Lanxess to be spun off to stockholders
"In the current stock market climate, a spin-off to Bayer stockholders is the best route to a listing for Lanxess. That way the present owners of Bayer's assets automatically remain the owners of the assets being transferred to Lanxess," explained Bayer CEO Werner Wenning, pointing out that Lanxess' business is developing in line with expectations.
Bayer had postponed a decision on whether to launch Lanxess by way of an initial public offering (IPO) or a spin-off to stockholders in order to await capital market developments. "We wanted to clarify the situation now, at the same time ensuring that the transaction will be fully accomplished. Now Lanxess' management can continue to focus on building the business," Wenning added.
Lanxess CEO-designate Dr. Axel C. Heitmann says he is pleased the Board decision on the form of the stock market listing has now been made. "We at Lanxess will continue working to get our new company off to a good start. We want to instill confidence in our future stockholders and convince them that Lanxess stock is a worthwhile investment."
Bayer's stockholders will take the final decision on the spin-off at an Extraordinary Stockholders' Meeting expected to be held in mid-November 2004. Details of how the spin-off will be carried out will be given in the Notice of the Meeting.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.